Moody National Bank Trust Division Makes New Investment in Novo Nordisk A/S $NVO

Moody National Bank Trust Division bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 11,352 shares of the company’s stock, valued at approximately $544,000.

A number of other hedge funds have also recently made changes to their positions in NVO. Quotient Wealth Partners LLC lifted its holdings in Novo Nordisk A/S by 2.0% during the 4th quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock valued at $463,000 after buying an additional 177 shares in the last quarter. Certuity LLC increased its position in shares of Novo Nordisk A/S by 3.6% during the fourth quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after acquiring an additional 177 shares during the period. Oakworth Capital Inc. raised its stake in shares of Novo Nordisk A/S by 41.6% during the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after acquiring an additional 182 shares in the last quarter. True North Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 3.9% in the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock valued at $270,000 after purchasing an additional 199 shares during the period. Finally, Revolve Wealth Partners LLC grew its stake in Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on NVO shares. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. BMO Capital Markets reiterated a “market perform” rating and set a $47.00 target price on shares of Novo Nordisk A/S in a report on Thursday. Finally, Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday. Five investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $65.81.

Novo Nordisk A/S Stock Up 3.1%

Shares of NYSE NVO opened at $45.90 on Friday. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $204.96 billion, a PE ratio of 11.22, a price-to-earnings-growth ratio of 4.06 and a beta of 0.76. The stock’s fifty day simple moving average is $46.96 and its two-hundred day simple moving average is $45.01. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%. As a group, analysts expect that Novo Nordisk A/S will post 3.39 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a dividend, which will be paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th will be paid a $0.5786 dividend. This represents a yield of 254.0%. The ex-dividend date is Monday, August 17th. Novo Nordisk A/S’s payout ratio is 42.79%.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Strong quarterly results and raised outlook: Novo Nordisk beat second-quarter revenue expectations by approximately 10% and adjusted EPS estimates by more than 20%. Revenue increased 7% year over year, operating profit rose 11%, and management lifted its 2026 sales and profit outlook for the second time this year. Novo Nordisk: The Market Has Lost Its Mind, Too Cheap To Ignore
• Positive Sentiment: Continued GLP-1 demand: International markets and obesity care continued to drive growth, while accelerating demand for the Wegovy pill supported the improved outlook. The company also retains substantial profitability and cash generation to fund research, development and shareholder returns. NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift
• Positive Sentiment: Patent enforcement win: A Dutch court ordered Ceban Ziekenhuisfarmacie to stop selling an infringing compounded semaglutide nasal spray, remove product listings and provide supply-chain information. The ruling could help protect Novo’s semaglutide franchise from unauthorized competition in the Netherlands. Novo Nordisk wins Dutch court injunction
• Neutral Sentiment: Novo declared a dividend of 0.5786 per share, payable August 25 to shareholders of record August 17. The reported 254% yield appears inconsistent with the stated dividend and should be treated cautiously pending confirmation. Novo Nordisk dividend and insider transactions announcement
• Negative Sentiment: Pipeline and competitive concerns remain the main overhang: Investors focused on weaker-than-expected Wegovy pill sales, a setback for the next-generation obesity treatment CagriSema, U.S. pricing pressure and the widening commercial lead of Eli Lilly’s GLP-1 portfolio. These issues overshadowed the earnings beat and guidance increase. The divide between Eli Lilly and Novo Nordisk is widening

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.